NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders

Rhea-AI Summary

NanoVibronix (NASDAQ: NAOV) reported significant growth in Q2 2024, with revenue reaching $817,000, over 2.5 times higher than Q2 2023. The company reduced its loss from operations by more than 30% to approximately ($674,000). Key highlights include:

1. Increased revenues from Veterans' Health System and Workers' Compensation markets
2. Strong balance sheet with $2.2 million cash and $2.4 million inventory
3. Progress in domestic sales channels, including VA facilities and DME distributors
4. International expansion in Australia, New Zealand, and the UK
5. Ongoing product development and research initiatives

The company remains focused on expanding distribution channels, nurturing relationships with accounts, and engaging consumers to drive profitable growth.

Positive

• Record Q2 revenue of $817,000, 2.5 times higher than Q2 2023
• Loss from operations reduced by over 30% to ($674,000)
• Strong balance sheet with $2.2 million cash and $2.4 million inventory
• Increased revenues from Veterans' Health System and Workers' Compensation markets
• GSA contract awarded to sales partner Delta Medical, expected to accelerate product adoption
• Expansion of DME distributor network for PainShield
• Progress in international markets: Australia, New Zealand, and UK
• Ongoing evaluation with German urologic pharmaceutical company for potential partnership
• University of Michigan initiating Randomized Control Trial study on UroShield efficacy

Negative

• Company still operating at a loss, albeit reduced
• Full reimbursement for UroShield in Australia and New Zealand markets still pending
• COVID-19 interrupted momentum in some business discussions

Insights

Financial Analyst

NanoVibronix's Q2 2024 results show promising growth. Revenue reached $817,000, a record for Q2 and over 250% increase from Q2 2023. The company narrowed its operating loss by 30% to $674,000. This improvement stems from increased sales in Veterans' Health System and Workers' Compensation segments, coupled with cost reductions.

The balance sheet remains solid with $2.2 million in cash and $2.4 million in inventory. The GSA contract effective May 1, 2024, could accelerate product adoption in VA facilities. However, investors should note that while growth is evident, the company is still operating at a loss. The focus on reimbursement approvals and international expansion could be key drivers for future profitability.

Medical Device Expert

NanoVibronix's product portfolio, including UroShield®, PainShield® and WoundShield®, shows promise in addressing unmet medical needs. The increasing adoption of PainShield as an alternative to opioids for pain management is particularly noteworthy. The upcoming Randomized Control Trial (RCT) at the University of Michigan for UroShield could provide important clinical evidence to support its efficacy in reducing urinary tract infections and improving patient quality of life.

The company's focus on product development, aiming to improve therapy, reduce costs and "future-proof" components, demonstrates a commitment to innovation. However, the lack of specific details on these improvements and new product opportunities leaves some uncertainty about the potential impact on future sales and market position.

Market Research Analyst

NanoVibronix's market strategy appears well-targeted, focusing on key segments like Veterans' Health System and Workers' Compensation. The exclusive distribution agreements and GSA contract position the company favorably for growth in these areas. International expansion efforts, particularly in Australia, New Zealand and the UK, show potential for market diversification.

The ongoing evaluation with a German urologic pharmaceutical company could open significant opportunities in Europe. However, the success of these initiatives will depend on securing reimbursement approvals and effectively penetrating new markets. The company's emphasis on private label agreements and sector-specific distribution could lead to more predictable revenue streams, but execution risks remain. Investors should monitor progress on the stated near-term milestones as indicators of the company's ability to capitalize on its market opportunities.

ELMSFORD, N.Y.--(BUSINESS WIRE)-- NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the second quarter financials and recent business developments.

To Our Shareholders:

We are committed to our strategic vision of developing, improving and commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase stockholder value. We are focused on several areas that we believe will have a substantial impact on our growth and product adoption. Many of those areas of focus have begun showing positive results, as reflected in our most recent quarter’s financial results for the quarter ended June 30, 2024. Our products continue to deliver impressive outcomes with high patient satisfaction, with no reportable adverse events. Moreover, we are investing in sales improvement and long-term opportunities with all of our products.

Q2 Financial Results

We recorded revenues of approximately $817,000 for the quarter ended June 30, 2024, which is the largest amount of revenues we have ever recorded in the second quarter of any fiscal year and more than 2.5 times the revenue we generated for the same period in 2023. Compared to the quarter ended June 30, 2023, the loss from operations was reduced by more than 30% to approximately ($674,000). We continue to generate increased revenues from the Veterans’ Health System and Workers' Compensation market segments and our dealer network even as we continue to reduce operating costs. Our balance sheet remains strong, with approximately $2.2 million of cash and inventory of approximately $2.4 million as of June 30, 2024.

Domestic update

We continue to make progress in several channels of domestic sales and product adoption. Our Veterans' Affairs penetration continues to improve in terms of the number of facilities served, and we have added valuable sales resources in areas previously uncovered by our current sales partner, Delta Medical.

Delta Medical was awarded a GSA grant that we believe will provide for an accelerated uptick in product adoption within the Veterans' Health facilities. The GSA contract became effective on May 1, 2024, so we have yet to realize a full quarter impact. The GSA contract is expected to have a positive impact on both sales and adoption, as well as provide a significant competitive advantage, and we are optimistic that we will see the effects of the GSA in the second half of 2024. We are also optimistic about our future sales growth within this important business sector.

Additionally, we continue to make progress in the Workers’ Compensation area of our business, from multiple sales channels. Our Durable Medical Equipment (“DME”) exclusive distributor has been steadily delivering and expanding its reach through the addition of qualified and competent dealers, and we believe there is significant upside potential in this area. We are gratified to see the adoption of PainShield increase within both reimbursable market segments and become the accepted product of choice for the DME market. The PainShield product family is increasingly becoming a recognizable and acceptable standard for pain relief and the avoidance of opioids.

Reimbursement

Reimbursement is currently approved in the Veterans’ Health System and several Workers' Compensation plans, Third Party Administrators and insurance companies. Our revenues in these markets have grown and continue to grow substantially. Through our strategic, exclusive distributor partners for select markets, and through our direct sales efforts, we are seeing growth every month. The sales growth follows the payer and patient testimonials of superior product efficacy, which is heavily scrutinized in these markets. It is truly gratifying to witness the product loyalty and increased adoption of PainShield.

Reimbursement for UroShield remains in effect for the Veterans' Administration segment.

International update

We continue to make progress and generate additional sales in the Australian and New Zealand markets. Full reimbursement for UroShield is being considered in both markets, although the timing is unknown at this point in time. If reimbursement is granted, we believe there could be a significant increase in demand for our urology products.

In the U.K., we continue to leverage our contract with the National Health Services (“NHS”) Supply Chain and our supplies reimbursement through the NHS Prescription Services’ Drug Tariff, which became effective on November 1, 2023. We continue to make progress with our UroShield product and have experienced more interest since then. Our U.K. distributor, Peak Medical Limited, continues to add to its inventory and is actively pursuing market opportunities throughout the country.

Relative to the broader market in Europe, we are continuing our evaluation with a significant urologic pharmaceutical company based in Germany. Our previous announcement of the evaluation with Apogepha Pharmaceutical, Inc. provides more detail, the link of which can be found here. The synergy between the companies will provide for a mutually beneficial opportunity. We expect to provide updates regarding this matter in the near future.

Research

The University of Michigan will begin facilitating a gold standard Randomized Control Trial (RCT) study on the efficacy and patient satisfaction of patients utilizing UroShield. The research, which is being led by the Center for Research and Innovations in Special Populations (CRIISP), an experienced and highly accomplished research team, will be conducted primarily with nursing home residents and is aimed at studying the impact UroShield may have on reducing urinary tract infections, catheter blockages and pain and improving the quality of life of the patients studied. The first phase of the study was originally expected to include a validation pilot of up to 30 patients in advance of the full study. The full study is expected to include more than 300 patients. Reevaluating the pilot with the University of Michigan team, we mutually believe we can achieve the desired results of the pilot with just 20 patients, and at this time, we have 15 patients enrolled. We look forward to receiving the researchers’ conclusions on the pilot, and are hopeful of positive outcomes for patients in the broader study.

Product development

We have been working on several exciting improvements to the existing product portfolio as well as exploring new product opportunities. The goals of the product development are to improve the therapy, reduce costs and “future-proof” the componentry. The “kick-off” for the project began on time and the development process is progressing rapidly.

A look ahead

We remain focused on driving profitable growth by expanding and increasing our distribution and licensing channels, nurturing relationships with new and existing accounts and engaging consumers through a variety of creative mediums. Today, we have initial distribution agreements in place, a solid manufacturing partner and the necessary working capital to meet existing and anticipated near-term demand.

We continue to negotiate for sector-specific private label agreements. This strategy is intended to develop long-lasting, profitable, forecastable revenue. COVID-19 interrupted our momentum, but these discussions are moving forward.

In the near-term, we are primarily focused on achieving the following milestones:

• Supplementing distribution to achieve broader geographic coverage in both VA and Workers' Compensation channels
• Selection of UroShield distribution to key markets
• Adding market segment specific distribution for PainShield in the U.S.
• Finalizing a private label partnership for PainShield in the U.S.
• Expanding UroShield distribution throughout the world.

Thank you for your continued support. We remain optimistic and motivated to deliver improved results for 2024.

Kind regards,

Brian Murphy
Chief Executive Officer

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240821272005/en/

Investor Contact:

Brett Maas, Managing Principal, Hayden IR, LLC

brett@haydenir.com

(646) 536-7331

Source: NanoVibronix, Inc.

FAQ

What was NanoVibronix's (NAOV) revenue for Q2 2024?

NanoVibronix reported revenue of $817,000 for Q2 2024, which is the largest amount ever recorded in the second quarter of any fiscal year for the company.

How much did NanoVibronix (NAOV) reduce its loss from operations in Q2 2024?

NanoVibronix reduced its loss from operations by more than 30% to approximately ($674,000) compared to the same quarter in the previous year.

What is the cash position of NanoVibronix (NAOV) as of June 30, 2024?

As of June 30, 2024, NanoVibronix had approximately $2.2 million in cash and $2.4 million in inventory.

What markets are driving revenue growth for NanoVibronix (NAOV)?

NanoVibronix is generating increased revenues from the Veterans' Health System, Workers' Compensation market segments, and its dealer network.

What is the status of the University of Michigan study on NanoVibronix's (NAOV) UroShield?

The University of Michigan is initiating a Randomized Control Trial study on UroShield's efficacy, with 15 out of 20 patients currently enrolled in the pilot phase.